Regulus Therapeutics Company Profile (NASDAQ:RGLS)

Analyst Ratings

Consensus Ratings for Regulus Therapeutics (NASDAQ:RGLS) (?)
Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $10.30 (200.29% upside)

Analysts' Ratings History for Regulus Therapeutics (NASDAQ:RGLS)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016FBR & CoReiterated RatingOutperform$30.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016WedbushReiterated RatingOutperform$35.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016Needham & Company LLCLower Price TargetBuy$25.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$16.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016Chardan CapitalLower Price TargetBuy$20.00 -> $13.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Wells Fargo & Co.Initiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2015GuggenheimInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Deutsche Bank AGSet Price TargetBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Regulus Therapeutics (NASDAQ:RGLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/2/2016Q1($0.33)($0.40)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2016Q415($0.25)($0.14)$5.09 million$10.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.37)($0.25)$2.85 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.29)($0.41)$2.40 million$3.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.26)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015($0.21)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014($0.23)($0.23)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.19)($0.29)$3.19 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.14)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014($0.13)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/19/2012Q312($15.98)$3.81 million$2.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Regulus Therapeutics (NASDAQ:RGLS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.33)($0.32)($0.33)
Q2 20162($0.42)($0.32)($0.37)
Q3 20162($0.44)($0.32)($0.38)
Q4 20162($0.45)($0.32)($0.39)
Q1 20171($0.43)($0.43)($0.43)
Q2 20171($0.45)($0.45)($0.45)
Q3 20171($0.47)($0.47)($0.47)
Q4 20171($0.50)($0.50)($0.50)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Regulus Therapeutics (NASDAQ:RGLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Regulus Therapeutics (NASDAQ:RGLS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Regulus Therapeutics (NASDAQ:RGLS)
DateHeadline
07/22/16 09:03 AMIs Buying Regulus Therapeutics Inc Here a Winning Strategy? - Press Telegraph
07/22/16 09:03 AMRegulus Therapeutics Inc. (NASDAQ:RGLS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 09:03 AMRegulus Therapeutics Inc. (RGLS) Jumps 5.28% on July 20 - Equities.com
07/20/16 06:59 PMHC Stocks Indications: Regulus Therapeutics Inc (NASDAQ:RGLS), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release)
07/20/16 06:59 PMRegulus Therapeutics Inc. (RGLS) Drops 7.2% on July 19 - Equities.com
07/19/16 07:05 AMNotable Stock's Buzzers: Comcast Corporation (NASDAQ:CMCSA), Regulus Therapeutics Inc (NASDAQ:RGLS) - NYSE Journal (press release)
07/19/16 07:05 AMRegulus Therapeutics Inc. (RGLS) Updated Price Targets - FTSE News
07/15/16 05:07 PMRegulus Therapeutics Inc. (RGLS) Jumps 6.6% on July 15 - Equities.com
07/14/16 06:22 PMInvestor News: Investigation of Regulus Therapeutics Inc (NASDAQ:RGLS) over potential Violations of Securities Laws - GroundReport
07/14/16 06:22 PMHow Analysts Feel About Regulus Therapeutics Inc (NASDAQ:RGLS)? - Consumer Eagle
07/14/16 09:44 AMInvestor News: Investigation of Regulus Therapeutics Inc (NASDAQ:RGLS) over potential Violations of Securities Laws
07/12/16 10:30 AMRegulus Therapeutics Incorporated (NASDAQ:RGLS) Sellers Increased By 1.49% Their Shorts - Consumer Eagle
07/10/16 05:22 PMBroker Outlook For Regulus Therapeutics Inc. (RGLS) - Fiscal Standard
07/10/16 05:22 PMNext Weeks Broker Price Targets For Regulus Therapeutics Inc. (RGLS) - Fiscal Standard
07/07/16 06:12 PMRegulus Therapeutics Inc. Stock Momentum Hits Extreme Weakness - CML News
07/07/16 06:12 PMRegulus Therapeutics Inc. (RGLS) Jumps 7.74% on July 06 - Equities.com
07/07/16 08:54 AMInvestor Investigation of Regulus Therapeutics Inc (NASDAQ:RGLS) over Potential Violations of Securities Laws
07/06/16 06:25 PMHC Stocks Buzzer: Regulus Therapeutics Inc (NASDAQ:RGLS), Shire PLC (ADR) (NASDAQ:SHPG) - share market updates (press release)
07/06/16 06:25 PMRegulus Therapeutics Inc. (RGLS) is Trading Higher on Unusual Volume for July 04 - Equities.com
07/06/16 06:25 PMRegulus Therapeutics Inc. (RGLS) Jumps 11.07% on July 04 - Equities.com
07/05/16 10:33 AMBiotechnology Stocks Technical Review - Medivation, ACADIA Pharma, Regulus Therapeutics, and Vascular Biogenics
07/05/16 07:00 AMRegulus to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [PR Newswire] - LA JOLLA, Calif., July 5, 2016 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...
06/30/16 06:23 PMAnalysts Review of Stocks: Eli Lilly and Company (NYSE:LLY) , Regulus Therapeutics Inc. (NASDAQ:RGLS) - Street Updates
06/30/16 06:23 PMHot Stock seeking Investors: Regulus Therapeutics Inc. (NASDAQ:RGLS) - News Oracle
06/30/16 06:23 PMRegulus Therapeutics Inc. (RGLS) Hits New 52-week Low During June 28 Session - Equities.com
06/30/16 08:55 AMRegulus Therapeutics Inc (NASDAQ:RGLS) Slashed By Half Following An FDA Study Halt Notice
06/30/16 08:55 AMRegulus Therapeutics Inc. (RGLS) Plunged To A New Low On FDA Clinical Hold
06/29/16 05:59 PMRegulus Therapeutics Inc. (NASDAQ:RGLS) Company Rating and Target Watch - Telanagana Press
06/29/16 05:59 PMMix Cap Most Movers- McKesson (NYSE:MCK), Regulus Therapeutics (NASDAQ:RGLS), AECOM (NYSE:ACM) - Seneca Globe
06/29/16 05:59 PMRegulus Therapeutics Inc (RGLS) PT Cut On Clinical Hold News, Says Wedbush - TCC
06/29/16 05:59 PMHot Stock under Consideration: Regulus Therapeutics Inc. (NASDAQ:RGLS) - News Oracle
06/29/16 08:53 AMEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Regulus Therapeutics Inc. – RGLS
06/29/16 08:53 AMRegulus Therapeutics (NASDAQ:RGLS) target price lowered to $9, reported today by FBR Capital
06/28/16 06:02 PMINVESTOR NOTICE: Lundin Law PC Announces Investigation Of Regulus Therapeutics Inc. And Advises Investors With Losses to Contact the Firm
06/28/16 06:02 PMNeedham disclosed (NASDAQ:RGLS) Regulus Therapeutics, cutting its stock price target to $10 today
06/28/16 06:02 PMRegulus Reports Clinical Hold of RG-101
06/28/16 12:31 PMMid-Day Market Update: Dow Surges 150 Points; Regulus Therapeutics Shares Tumble -   Midway through trading Tuesday, the Dow traded up 0.88 percent to 17,291.76 while the NASDAQ climbed 1.54 percent to 4,665.27. The S&P also rose, gaining 1.01 percent to 2,020.80. Leading and Lagging Sectors On Tuesday, energy shares rose by 1.9 percent. Top gainers in the sector included EV Energy Partners, L.P. (NASDAQ: EVEP) and Pioneer Energy Services Corp (NYSE: PES). In trading on Tuesday, utilities shares rose by just 0.2 percent. Meanwhile, top losers in the sector included South Jersey Industries Inc (NYSE: SJI), down 2 percent, and Vectren Corp (NYSE: VVC), down 2 percent. Top Headline Gannett Co Inc announced its plans to acquire ReachLocal Inc. for $4.60 per share. Gannett projects the deal to close in the third quarter. Equities Trading UP Xencor Inc (NASDAQ: XNCR) shares shot up 39 percent to $17.37 after the company announced strategic collaboration with Novartis AG (ADR) (NYSE: Full story available on Benzinga.com
06/28/16 12:31 PM7 Biggest Mid-Day Losers For Tuesday -   Regulus Therapeutics Inc (NASDAQ: RGLS) shares dropped 45.6 percent to $2.72 after the FDA said it had placed the company’s lead product candidate, RG-101 for the treatment of hepatitis C virus (HCV) infection, on clinical hold. Celyad SA (ADR) (NASDAQ: CYAD) shares fell 36.5 percent to $26.97. Celyad reported that its CHART-1 Phase 3 trial did not ...Full story available on Benzinga.com
06/28/16 10:56 AMRegulus Therapeutics (RGLS) Announces Clinical Hold on RG-101
06/28/16 10:56 AMRegulus Therapeutics Inc (RGLS) Price Target Slashed On News of Clinical Hold: Wedbush Securities
06/28/16 10:56 AMRegulus Therapeutics Inc. (RGLS) Has Plunged To A New Low On FDA News
06/28/16 10:56 AMAnalyst Downgrades: Tesla Motors Inc, Regulus Therapeutics Inc, and Dow Chemical Co
06/28/16 10:56 AMAre Markets Missing A Regulus Therapeutics Inc (NASDAQ:RGLS) Opportunity?
06/28/16 10:04 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Regulus Therapeutics Inc. - [Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Regulus Therapeutics Inc. concerning possible violations of federal securities laws.
06/28/16 09:22 AMShareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Regulus Therapeutics Inc. (RGLS) - [PR Newswire] - NEW YORK, June 28, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Regulus Therapeutics Inc. ...
06/28/16 08:14 AMWhy Regulus Is Tanking -
06/28/16 07:38 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regulus Therapeutics Inc. - RGLS - [PR Newswire] - NEW YORK, June 28, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regulus Therapeutics Inc. ("Regulus" or the Company) (RGLS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.
06/27/16 11:18 PMRegulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied? - Another case of jaundice for RG-101.
06/27/16 06:03 PMShare Update and Earnings Review for Regulus Therapeutics Inc. (NASDAQ:RGLS) - Press Telegraph
06/27/16 06:03 PMStock Touching a Recent Low: Regulus Therapeutics Inc. (NASDAQ:RGLS) - Press Telegraph

Social

About Regulus Therapeutics

Regulus Therapeutics logoRegulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Its development programs include microRNA target miR-122, miR-21, RG-012, miR-103/107, miR-19, miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs, RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RGLS
  • CUSIP: 75915K10
Key Metrics:
  • Previous Close: $3.42
  • 50 Day Moving Average: $4.37
  • 200 Day Moving Average: $5.96
  • P/E Ratio: N/A
  • P/E Growth: -0.06
  • Market Cap: $181.04M
  • Beta: 1.82
  • Current Year EPS Consensus Estimate: $-1.54 EPS
  • Next Year EPS Consensus Estimate: $-1.62 EPS
Additional Links:
Regulus Therapeutics (NASDAQ:RGLS) Chart for Sunday, July, 24, 2016